YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.

Inclusion Criteria:

• Patient is hospitalized within 2 days before the study and has more than 1 basic VTE risks
• Complete bed rest is required in the fist day of hospitalization and at least 4 days hospitalization
• Written informed consent obtained

Exclusion Criteria:

• Subject has history of deep vein thrombosis and/or pulmonary embolism
• Subject has a hemorrhagic disorder and/or coagulation disorder
• Subject has had clinically important bleeding occurred within 90 days prior to obtaining informed consent
• Subject has an acute bacterial endocarditis
• Subject has uncontrolled severe or moderate hypertension, retinopathy, myocardial infarction or stroke
• Subject is receiving anticoagulants/antiplatelet agents
• Subject has a body weight less than 40 kg
• Major trauma, major surgery, eye, spinal cord and/or brain surgery within 90 days prior to obtaining informed consent, or the subject scheduled for these surgeries during the study periods